In this part of his Pharmaceutical Executive video interview, Jonathan Scheinberg, of the Northeast Science and Technology Center, explains how can companies position themselves to attract VC/federal funding, and identifies potential regulatory and policy implications of these trends.
In this part of his Pharmaceutical Executive video interview, Jonathan Scheinberg, of the Northeast Science and Technology Center, discusses what specific areas of research and development are likely to benefit the most from this influx of of venture capital and federal funding.
In this part of his Pharmaceutical Executive video interview, Jonathan Scheinberg, of the Northeast Science and Technology Center, discusses strategies companies employ to effectively identify and dispose of non-core assets while minimizing disruption to their operations.
In this part of his Pharmaceutical Executive video interview,Jonathan Scheinberg, of the Northeast Science and Technology Center, talks about strategies companies can adopt to attract and retain top talent in these competitive mega campus locations.
In this part of his Pharmaceutical Executive video interview, Jonathan Scheinberg, of the Northeast Science and Technology Center, identifies key factors that pharmaceutical and biotech companies should consider when selecting and developing mega campuses.
In this part of his Pharmaceutical Executive video interview, Jonathan Scheinberg, of the Northeast Science and Technology Center, describes what makes up a mega campus.
In this part of their Pharmaceutical Executive video interview, UpScriptHealth's Peter Ax, Founder and CEO, and George Jones, Chief Operations Officer, share their predictions for the future of telehealth and its role in providing access to essential medications like weight loss drugs
In this part of their Pharmaceutical Executive video interview, UpScriptHealth's Peter Ax, Founder and CEO, and George Jones, Chief Operations Officer, discuss how UpScriptHealth is working to increase access to legitimate weight loss medications, especially for those in underserved communities.
In this part of their Pharmaceutical Executive video interview, UpScriptHealth's Peter Ax, Founder and CEO, and George Jones, Chief Operations Officer, explain how their company guarantees the authenticity of the medications it dispenses, and the measures are in place to prevent counterfeit drugs from entering their supply chain.
In this part of their Pharmaceutical Executive video interview, UpScriptHealth's Peter Ax, Founder and CEO, and George Jones, Chief Operations Officer, comment on how Eli Lilly's recent announcement to sell Zepbound DTC will impact the counterfeit weight loss drug issue.
In this part of their Pharmaceutical Executive video interview, UpScriptHealth's Peter Ax, Founder and CEO, and George Jones, Chief Operations Officer, discuss the issue of counterfeit weight loss drugs, and the potential health risks associated with them.
In an interview with Pharm Exec Associate Editor Don Tracy, Joseph Mikhael, MD, chief medical officer, IMF, discusses challenges of access and advancement of myeloma therapies.
In an interview with Pharm Exec Associate Editor Don Tracy, Joseph Mikhael, chief medical officer, IMF, offers a glimpse at multiple initiatives that the IMF is working towards to improve myeloma treatment globally.
In an interview with Pharm Exec Associate Editor Don Tracy, Joseph Mikhael, MD, chief medical officer, IMF, explains the goals of the inaugural Iceland Cycling Expedition.
In an interview with Pharm Exec Associate Editor Don Tracy, Carlos Doti, VP, Head of Medical Affairs, US Oncology Business Unit, AstraZeneca, discusses a number of oncology targets in the works at AstraZeneca.
In an interview with Pharm Exec Associate Editor Don Tracy, Carlos Doti, VP, Head of Medical Affairs, US Oncology Business Unit, AstraZeneca, talks PARP inhibitors in cancer treatment and the history of Lynparza.
In this part of his Pharmaceutical Executive video interview, Brian Hillberdink, EVP, LEO Pharma and President of LEO Pharma's US affiliate, identifies key challenges and opportunities for adapting LEO's business model to be able to succeed in a competitive US market.
In this part of his Pharmaceutical Executive video interview, Brian Hillberdink, EVP, LEO Pharma and President of LEO Pharma's US affiliate, talks about how they balance the need for profitability with the mission of providing treatments for rare diseases.
In this part of his Pharmaceutical Executive video interview, Brian Hillberdink, EVP, LEO Pharma and President of LEO Pharma's US affiliate, discusses how is LEO Pharma positioning itself to capitalize on the unmet needs, patient centric initiatives, and more.
In an interview with Pharm Exec Associate Editor Don Tracy, Carlos Doti, VP, head of medical affairs, US oncology business unit, AstraZeneca, provides an update on current research efforts for Lynparza and discusses its impact on cancer patients over the past decade.
In this part of her Pharmaceutical Executive video interview, Charlotte Owens, MD, FACOG, Head of Medical Affairs and Outcomes Research at Organon, discusses how she's using her in-practice experience as an OB-GYN to inform Organon's strategic approach to addressing maternal health challenges.
In an interview with Pharm Exec Associate Editor Don Tracy, Carlos Doti, VP, head of medical affairs, US oncology business unit, offers his thoughts on the evolution of Lynparza across indications such as breast, prostate, and pancreatic cancers.
In this part of her Pharmaceutical Executive video interview, Charlotte Owens, MD, FACOG, Head of Medical Affairs and Outcomes Research at Organon, identifies Organon's efforts to invest in research, education, and its pipeline to focus on critical areas of need in maternal health.
In this part of her Pharmaceutical Executive video interview, Charlotte Owens, MD, FACOG, Head of Medical Affairs and Outcomes Research at Organon, talks about the most critical to close the gaps in R&D for maternal health solutions and how feasible the fixes are.
In this part of her Pharmaceutical Executive video interview, Charlotte Owens, MD, FACOG, Head of Medical Affairs and Outcomes Research at Organon, discusses the societal implications of maternal health issues both short and long term.
In this part of his Pharmaceutical Executive video interview, Joshua M. Cohen, MD, MPH, FAHS, Chief Medical Officer, Braeburn discusses how the findings from this study contribute to addressing treatment gaps and improving patient outcomes for those struggling with fentanyl dependence, ensuring broader patient access to BRIXADI®, and more.
In this part of his Pharmaceutical Executive video interview, Joshua M. Cohen, MD, MPH, FAHS, Chief Medical Officer, Braeburn discusses data from the Phase III trial recently published in JAMA and how confident they are in the generalizability of these findings to a real-world treatment setting.
In this part of his Pharmaceutical Executive video interview, Fabrice Chouraqui, CEO of Cellarity, discusses some other potential areas where Cellarity's approach could be particularly impactful.
In this part of his Pharmaceutical Executive video interview, Fabrice Chouraqui, CEO of Cellarity, speaks about the broader implications of Cellarity's approach for the drug discovery field.
In this part of his Pharmaceutical Executive video interview, Fabrice Chouraqui, CEO of Cellarity, discusses how their AI/ML approach differs and the advantages it offers in terms of uncovering novel treatment opportunities.
